Login to Your Account

Marketing exclusivity reduces the wind beneath Arymo's wings

By Mari Serebrov
Regulatory Editor

Wednesday, January 11, 2017

A recently awarded three-year marketing exclusivity for a yet-to-be-launched drug grounded a soaring rally over Monday's FDA approval of Egalet Corp.'s Arymo, an abuse-deterrent, extended-release opioid.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription